SYSTIMMUNE Trademark

Trademark Overview

On Thursday, February 16, 2017, a trademark application was filed for SYSTIMMUNE with the United States Patent and Trademark Office. The USPTO has given the SYSTIMMUNE trademark a serial number of 87339289. The federal status of this trademark filing is REGISTERED as of Tuesday, April 26, 2022. This trademark is owned by SYSTIMMUNE, INC.. The SYSTIMMUNE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment of oncological disorders, autoimmune disorders, pain and inflammation; biochemicals, namely, antibodies for in vivo studies
systimmune

General Information

Serial Number87339289
Word MarkSYSTIMMUNE
Filing DateThursday, February 16, 2017
Status700 - REGISTERED
Status DateTuesday, April 26, 2022
Registration Number6713541
Registration DateTuesday, April 26, 2022
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 26, 2017

Trademark Statements

Description of MarkThe mark consists of three concentric circles with the lower portion bisected by two lines forming a stylized person above the stylized word "Systimmune".
Goods and ServicesPharmaceutical preparations for human use for the treatment of oncological disorders, autoimmune disorders, pain and inflammation; biochemicals, namely, antibodies for in vivo studies
Pseudo MarkSYSTEM IMMUNE
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 23, 2017
Primary Code005
First Use Anywhere DateWednesday, August 12, 2020
First Use In Commerce DateWednesday, August 12, 2020

Trademark Owner History

Party NameSYSTIMMUNE, INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressRedmond, WA 98052
Party NameSYSTIMMUNE, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRedmond, WA 98052
Party NameSYSTIMMUNE, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRedmond, WA 98052

Trademark Events

Event DateEvent Description
Tuesday, May 10, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, May 10, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 10, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, May 10, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, May 10, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 10, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, April 26, 2022REGISTERED-PRINCIPAL REGISTER
Thursday, March 24, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, March 23, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, February 23, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 22, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 22, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 19, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 19, 2021NON-FINAL ACTION E-MAILED
Thursday, August 19, 2021SU - NON-FINAL ACTION - WRITTEN
Tuesday, July 20, 2021ASSIGNED TO EXAMINER
Friday, February 26, 2021STATEMENT OF USE PROCESSING COMPLETE
Monday, February 22, 2021USE AMENDMENT FILED
Monday, February 22, 2021TEAS STATEMENT OF USE RECEIVED
Friday, September 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 3, 2020SOU EXTENSION 5 GRANTED
Tuesday, August 18, 2020SOU EXTENSION 5 FILED
Tuesday, August 18, 2020TEAS EXTENSION RECEIVED
Saturday, February 15, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 13, 2020SOU EXTENSION 4 GRANTED
Thursday, February 13, 2020SOU EXTENSION 4 FILED
Thursday, February 13, 2020TEAS EXTENSION RECEIVED
Saturday, August 31, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, August 31, 2019CORRECTED NOA E-MAILED
Friday, August 30, 2019SOU EXTENSION 3 GRANTED
Tuesday, August 20, 2019SOU EXTENSION 3 FILED
Friday, August 30, 2019DIVISIONAL PROCESSING COMPLETE
Tuesday, August 20, 2019DIVISIONAL REQUEST RECEIVED
Thursday, August 29, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 20, 2019TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, August 20, 2019TEAS EXTENSION RECEIVED
Friday, February 22, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 20, 2019SOU EXTENSION 2 GRANTED
Wednesday, February 20, 2019SOU EXTENSION 2 FILED
Wednesday, February 20, 2019TEAS EXTENSION RECEIVED
Saturday, August 18, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 16, 2018SOU EXTENSION 1 GRANTED
Thursday, August 16, 2018SOU EXTENSION 1 FILED
Thursday, August 16, 2018TEAS EXTENSION RECEIVED
Tuesday, February 20, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 26, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 26, 2017PUBLISHED FOR OPPOSITION
Wednesday, December 6, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 8, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 3, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 2, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 2, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 10, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 10, 2017NON-FINAL ACTION E-MAILED
Wednesday, May 10, 2017NON-FINAL ACTION WRITTEN
Tuesday, May 9, 2017ASSIGNED TO EXAMINER
Friday, February 24, 2017NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, February 23, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, February 20, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

systimmune disorders biochemicals namely antibodies studies vivo inflammation autoimmune human preparations